This protocol was designed and developed by the Radiation Therapy Oncology Group (RTOG) of the American College of Radiology (ACR). It is intended to be used only in conjunction with institution-specific IRB approval for study entry. No other use or reproduction is authorized by RTOG nor does RTOG assume any responsibility for unauthorized use of this protocol.
INDEX
The following questions will be asked at Study Registration: 4, or N positive). Surgery has remained the mainstay of treatment of these cancers but because of high local recurrence rates (20-60%) , adjunctive chemoradiation has become standard practice for treatment of advanced cancers (> T 3 ). 1 Until recently adjunctive therapy consisted primarily of postoperative chemoradiation as established by the GITSG 2 , NCCTG 3 studies and intergroup studies. 4 However, data from the Swedish national trial 5 indicates that preoperative radiation may be a potentially better approach to treatment of this disease than postoperative radiation, both in terms of local control and reduced toxicity. This is especially true for tumors with extension into the perirectal fat and involvement of adjacent structures (stages T 3 ,T 4 
or N+).
Historically preoperative radiation utilized in low dose regimens of 20-30 Gy in 1.8-2.0 Gy fractions had proven ineffective. More recent data utilizing high dose preoperative radiation appears to be significantly more effective in increasing resectability rates 5, 6 , improving the options for sphincter preservation surgery 7, 8 , reducing local recurrence and improving survival of patients. 9, 10 In single institutional studies preoperative radiation using a high total radiation dose of 45 Gy + boost has consistently yielded high rates of local control (< 90%) and overall survival in the 70%-80% range. 11, 12 Pathological complete response following preoperative radiation alone has been reported in approximately 10% of patients. More recently preoperative radiation has been combined with cytotoxic agents, especially 5-flourouracil as a radiation sensitizer in an effort to increase the downstaging of tumors and improve the efficacy of treatment. A variety of chemotherapeutic approaches and radiation schedules have been utilized in single institutional studies and have resulted in a range of pathological complete responses of 10%-50%. [13] [14] [15] [16] [17] [18] Patient selection, radiation dose, treatment technique, and mode of drug delivery can significantly affect these rates of complete response. Reporting of treatment related toxicity also is variable and does not lend itself to comparison of the most effective regimen in the preoperative management of these cancers. This study is therefore proposed to examine, in a randomized phase II fashion, several of the currently available chemoradiation schedules to establish the most effective pre-operative treatment regimen as measured by pathological complete response rates and assess the toxicity of these regimens prior to considering a future phase III study for the management of this disease.
CPT-11 Rationale
The nuclear enzyme topoisomerase I has been recently recognized as the target for the anti-cancer drug irinotecan (CPT-11). CPT-11 (7-ethyl-10-[4-(l-piperidino) -l-piperidinol carbonyloxy camptothecin) is a water-soluble analogue of camptothecin synthesized in an attempt to identify camptothecin derivatives with aqueous solubility and antitumor activity. CPT-11 is a prodrug that undergoes deesterification in vivo to yield SN-38, a metabolite that is 1000-fold more potent than the parent compound in vitro.
Background on Camptothecins as Antitumor Agents
Camptothecin is a plant alkaloid obtained from the Camptotheca acuminata tree. The original clinical preparation, camptothecin sodium, was evaluated in clinical trials in the late 1960s and early 1970s but was abandoned due to severe and unpredictable hemmorrhagic cystitis. Irinotecan (CPT-11) is a semisynthetic derivative of camptothecin that possesses greater aqueous solubility, greater in vitro and in vivo activity, and is associated with less severe and more predictable toxicity than camptothecin. 16 Both camptothecin and CPT-11 are potent inhibitors of topoisomerase I, a nuclear enzyme that plays a critical role in DNA replication and transcription. The enzyme functions normally to cause transient breaks in a single strand of DNA that release the torsional strain caused by synthesis of a new strand of DNA or RNA around a double helix. The camptothecins target this topo I-DNA complex, known as the "cleavable complex." Once bound to the cleavable complex, the camptothecins inhibit realigning of the parent DNA, thereby halting nucleic acid synthesis in the cell and leading to cell death. 16 
Bioactivation of CPT-11 to SN-38
CPT-11 is converted by carboxylesterases to its more active metabolite, SN-38. In vitro, SN-38 is 250 to 1,000-fold more potent than CPT-11 as an inhibitor of topoisomerase I activity. Similar to camptothecin and its other analogues (e.g., topotecan), both CPT-11 and its more active metabolite, SN-38, are reversibly hydrolized from active lactone forms to hydroxy acid (carboxylate) forms. This hydrolysis is pHdependent, with equilibrium favoring the hydroxy acid form at physiological pH. The closed lactone ring is a structural requirement for activity of the camptothecins, since studies have demonstrated that the openring hydroxy acid form is a less potent inhibitor of topoisomerase I and a much less potent antitumor agent. 16 The enzymatic cleavage (hydrolysis) of the carbamyl bond of CPT-11 to form the active species SN-38 has been shown to be mediated by hepatic microsomal and serum carboxyl-esterase in animals. These serine hydroxylases were found in hepatic microsomes, kidney, lung, intestine, brain, and erythrocytes. The ability of various human tissues to produce SN-38 from CPT-11 was also compared E 1. Enzymatic hydrolysis was fastest in human liver (42.4 ng SN-38/mg protein/hour) with the kidney showing the second highest activity at 24% of the liver value. Activity in normal spleen, lung, and pancreatic tissue ranged between 16% to 18% of the liver value. Liver tumors produced significant, but slightly lower, amount of SN-38 than normal liver tissue F 1. Based on these results, human liver was proposed to be the major site of bioactivation of CPT-11, with extrahepatic metabolism in other normal and tumor tissues likely. 16 
Clinical Pharmacokinetics of CPT-11 and SN-38
The mean terminal half-life of SN-38 in plasma is slightly longer than that for CPT-11: 11.5 @ 3.8 hours versus 6.3 ± 2.2 hours (lactone forms). Peak plasma concentrations for CPT-11 occur at the end of the infusion. The time to peak SN-38 concentration is highly interpatient dependent and occurs 30-90 minutes after the end of infusion. 1 Murine studies suggest that the liver may concentrate CPT-11, convert CPT-11 to SN-38, and eliminate via biliary excretion CPT-11, SN-38 and the glucoronide conjugate of SN-38 (SN-38G). In rats, 55% of radiolabeled CPT-11 was excreted unchanged in the bile within 24 hours while 21.7% was transferred to SN-38. Overall, 73% of the radioactivity could be recovered from the feces of rats and 25% from the urine. It recently was demonstrated that plasma concentrations of SN-38G in patients occur 0.5 to three hours after the SN-38 peak and that plasma levels generally exceeded that of SN-38. In one patient, bile concentrations of CPT-11 were 10 to 560-fold higher than plasma concentrations during the-first six hours following administration, whereas bile concentrations of SN-38 were 2 to 9 fold higher. Renal clearance has not been reported to be a major route of elimination for these compounds in humans. 16 
Phase II Trials of CPT-11 in Previously Untreated Patients

CPT-11 and Irradiation
Preliminary preclinical and clinical studies demonstrate a synergistic effect of CPT-11 and radiation and suggest radiosensitizing activity of CPT-11. It has been suggested that CPT-11 may potentiate the lethal effects of ionizing radiation by attaching to the DNA-topoisomerase I adducts in sites of DNA single strand breaks (SSBs). Subsequently, the stabilized CPT-11-TOPO1-DNA complexes interact with advancing replication forks during the S-phase of the cell cycle converting SSBs into irreversible DNA double strange breaks resulting in cell death. Fractionated irradiation synchronizes and resorts the tumor cell population, leaving the majority of cells in the S phase of the cell cycle, and thus more sensitive to CPT-11 treatment.
Although radiation enhancement with CPT-11 has been demonstrated in vivo, the optimal dose and sequencing of irradiation with CPT-11 has not been examined.
A phase I/II study of weekly irradiation irinotecan in patients with local advanced non-small cell lung cancer demonstrated responses and manageable toxicities. Doses of CPT-11 started at 30 mg/m 2 and was escalated to 45 and 60 mg/m 2 /week. Twenty-six eligible patients, the DLT were esophagitis, pneumonitis and diarrhea. The MTD was estimated to be 60 mg/m 2 and the recommended dose for phase II study was 45 mg/m 2 . In this phase II study, out of 24 evaluable patients, 2 achieved a CR and 16 attained a PR, resulting in over all response rate of 76%. The conclusion was that a combination of concurrent weekly CPT-11 and RT is feasible and active for locally advanced NSCLC.
1.8
Completed Non-pregnant, non-lactating due to the combined effects of chemotherapy and pelvic irradiation 3.1. 4 White blood count of > 4000 per ml and platelet count > 130,000 per ml; liver and renal function tests (See Section 4.3) WNL. Bilirubin ≤ 1.5 x upper normal limit 3.1. 5 Zubrod performance status 0-1 3.1. 6 No concurrent malignancies except inactive non-melanoma skin cancer, in situ carcinoma of the cervix, synchronous colonic cancer if the synchronous tumor is Tis or T1 and has been completely resected; no previous invasive cancer unless the patient has been disease free for at least 5 years 3.1. 7 No other serious medical illnesses 3.1.8
Signed study-specific informed consent prior to randomization 3.1. 9 Pretreatment evaluations must be completed as specified in Section 4.0. Gy; fixed T4 patients will receive a boost dose of 14.4 Gy which will be delivered to a conedown volume including the posterior half of the pelvis or by a 3D conformal technique (tumor plus 2-2.5 cm).
Conventional (Arm 2)
Conventional doses of 1.8 Gy per fraction, five fractions per week delivered with all fields treated every day. The total dose will be 45 Gy/25 fractions/five weeks. Clinical stage T3 patients will receive a boost dose of 5.4 Gy; fixed T4 patients will receive a boost dose of 9.0 Gy which will be delivered to a conedown volume including the posterior half of the pelvis or by a 3-D conformal technique (tumor plus 2-2.5 cm).
6.1.3
Modality: External beam photon radiation shall be used. Energy: Megavoltage radiation shall be used i.e., accelerator beams of energy no less than 6 MV. Equipment of 10 MV or higher energy is strongly recommended.
6.1.4
Field Definition The fields are designed to cover the primary disease, pelvic soft tissue, principal nodal drainage areas and perineum. Shaped fields or blocks will be used to shield non-essential tissue.
6.1.5
Minimum boundaries of whole pelvic fields: 6.1.5.1
Standard opposed anterior-posterior portals: Inferior -The minimum would be at least a 5 cm margin from the inferior extent of the cancer or the anal verge for the distal cancers as identified by a marker on simulation.
Lateral -2 cm lateral to the bony pelvis taken at its widest point. Superior -L5-S1 junction.
6.1.5.2
Standard opposed lateral portals: Superior -To correspond to A/P fields. Inferior -To correspond to A/P fields.
Anterior -This will cover the lower common and external iliac to 1 cm anterior to the symphysis pubis for anterior wall lesions and be at the mid symphysis for posterior lesions. Posterior -This must include the entire sacrum with a 1 cm margin for T4 lesions or 2 cm posterior to the presacrum for T3 lesions.
6.1.6
The boost field shall have a 3 cm margin around the tumor but must include the whole of the sacral hollow.
Treatment Planning 6.2.1
Treatment Dose For the following portal arrangements, the target dose shall be specified as follows:
For two opposed co-axial equally-weighted beams: on the central ray at mid-separation of beams 6.2.1. 2 For an arrangement of two or more intersecting beams: at the intersection of the central ray of the beams 6.2.1. 3 For complete rotation or arc therapy: in the plane of rotation at the center of rotation 6.2.1. 4 Other or complex treatment arrangements: at the center of the target volume 6.2.1. 5 The technique of using two opposing co-axial unequally-weighted fields is not recommended due to unacceptable hot spots and unacceptable dose inhomogenuity.
6.2.2
Total Treatment Dose 6.
2.2.1
Original Treatment Volume: The total dose to the prescription point shall be 45 Gy in 25 (1.8 Gy/fx) fractions for conventional RT and 45.6 Gy in 38 twice daily fractions (1.2 Gy/fx) for hyperfractionated RT.
6.2.2.2
Boost Volume: The cumulative dose within the boost volume to the prescription point shall be 50.4 to 54 Gy with conventional RT and 55.2-60 Gy with hyperfractionated RT.
6.2.3
Time-Dose Considerations 6.2.3.1
Daily Dose: The daily dose to the prescription point of original and boost volumes shall be 1.8 Gy daily with conventional RT and 1.2 Gy twice daily (≥ 6 hour intervals) with hyperfractionated RT.
6.2.3.2
Fractionation: Treatment shall be given five days per week. All radiation fields shall be treated once each day with conventional RT and twice a day with a ≥ 6-hour interval with hyperfractionated RT.
6.2.3.3
Dose Homogeneity: The dose throughout the treatment volume will be within 10% of the prescribed dose.
6.2.3.4
Treatment Modification: Uninterrupted treatment is planned. Treatment may be interrupted for acute toxicity. The specific reason(s) for treatment interruption will be recorded in the treatment summary. The patient will be examined at least once a week during the course of radiation with a CBC and platelets. RT interruption is to be minimized and is allowed only for regional symptoms. Venous access must be established utilizing venous access device (for example, Hickman, Infusaport). An ambulatory infusion pump will be utilized for this regimen. The specific pump will be selected by the treating investigator.
7.1.1.4
Because of the increased risk of catheter thrombosis, anticoagulation is recommended. Heparin 10,000 can be co-administered, mixed in the same infusion, with the dose of 5-FU to be delivered over one week's time. Alternatively, oral coumadin antiocoagulants 1 -2 mg daily can be prescribed. Platelets and coagulation parameters (Prothrombin Time, PT) should be monitored weekly for four weeks and then monthly, If heparin associated thrombocytopenia is noted heparin should be deleted. The dose of coumadin anticoagulants should be adjusted to be low enough so as not to prolong PT. Anticoagulation administration should be recorded on the flow sheet.
7.1.2
Chemistry 5-Fluorouracil is a fluorinated pyrimidine differing from the normal RNA substrate, uracil, by a fluorinated number 5 carbon. The chemical has a pH of 8.1, and the commercially available solution is buffered with NaOH to obtain an alkaline solution with a pH of around 9.0. The drug is both light sensitive and will precipitate at low temperatures or, occasionally, after a prolonged period at room temperature. The melting range of the solid is 280-284°C. At 25°C the solubility is 12.2 mg/ml in water, 5.5 mg/ml in 955 ethanol, and less than 0.1 mg/ml in chloroform. The molecular weight is 130.08.
7.1.3
Mechanism of Action The metabolism of 5-FU in the anabolic pathway blocks the methylation reaction of deoxyuridilic acid to thymidylic acid. In this fashion, 5-FU interferes with the synthesis of DNA. This creates a thymine deficiency that provides unbalanced growth and cell death. Prolonged administration of 5-FU by continuous infusion may favor 5-FU incorporation into RNA. 5-FU is rapidly absorbed by the tissues. Studies with radioactively labeled 5-FU administered i.v. have indicated passage of the drug through the blood brain barrier. Intravenous administration gives a half time of 5-7.5 minutes at a 15mg/kg dose. Following the i.v. administration of a single 14 mg/kg dose radioactively labeled drug, levels of 28 mcg/ml, 2-8 mcg/ml, and 0.72 mcg/ml in plasma were observed at 10 minutes, 2 hours, and 24 hours, respectively. The drug is largely catabolized in the liver and excreted in the form of nontoxic metabolites. Eighty percent of the drug is excreted as CO 2 from the lungs, and approximately 15% is excreted intact in the urine in 6 hours. Of this 90% is excreted in the first hour.
Known Side Effects and Toxicities
Mild nausea and vomiting, stomatitis, anorexia, diarrhea, alopecia, myelosuppression, cerebellar, skin, and cardiac toxicity have been observed.
7.1.5
Formulation Each 10 ml ampule contains 500 mg of the drug (50 mg/ml), adjusted to a pH of approximately 9 with sodium hydroxide. 
7.2.2
Stomatitis will be managed with oral and systemic analgesics, but when it severely limits oral caloric intake, 5-FU therapy will be withheld for 3-7 days. Erythema of the palms and sole associated with pain is also a side effect that may require treatment cessation, but usually does not occur during the early phases (week 1-3) of treatment. Patients with pre-existing peripheral neuropathy and diabetic patients will be instructed to report any subtle changes in their conditions.
7.2.3
If hemoglobin falls below < 10.5 g/dL and the cause is determined to be related to chemotherapy, the use of Procrit or Epogen (epoetin alpha) should be considered. Blood transfusions should be carefully recorded. No dose modifications will be required for toxicity Grades 1 or 2.
7.2.4
Nutritional counseling should occur if caloric intake declines or if weight loss > 5% of pretreatment weight occurs during the combined radiation and chemotherapy. Nutritional support will be provided via enteral alimentation if possible, but parenteral hyperalimentation may be employed during this period if it is deemed clinically necessary to complete protocol therapy safely.
7.2.5
If radiotherapy is interrupted due to treatment toxicity, chemotherapy will be delayed until radiotherapy resumes. If Grade 3 toxicity persists longer than two weeks, discontinue chemotherapy and consult study chair. If a Grade 3 toxicity recurs, consult study chair. 4 Toxicity Virtually all phase I and II studies of irinotecan have reported neutropenia and diarrhea as the doselimiting toxicities. It is expected that these toxicities will also be encountered in this trial. Other Grade 2-3 toxicities seen include nausea and vomiting, anorexia, abdominal cramping, cumulative asthenia, thrombocytopenia, renal insufficiency, increase in transaminase level and hair loss. Sporadic cases of pulmonary toxicity, manifested as shortness of breath and nonproductive cough, have also been reported.
7.3.5
Formulation The drug is supplied in two forms: 2 ml vials containing 40 mg of drug and 5 ml vials containing 100 mg of drug. The drug is supplied in brown vials and appears as a pale yellow transparent solution. CPT-11 vials must be stored in a cool, dry place, protected from light in a locked cabinet accessible only to authorized individuals. It is stable for at least three years at room temperature. Irinotecan is stable for at least 24 hours in glass bottles or plastic bags after reconstitution with D 5 W.
7.3.6
Supply for U.S. Sites (3-13-02) Commercially available.
7.3.7
Camptosar/CPT-11 and Loperamide Distribution for Canadian Study Sites (3-13-02) The CPT-11 supplied for this study will not be used for any other purpose other than for this study or administered other than as described in the protocol.
Shipments to Canada
Pharmacia Canada Inc. will ship CPT-11 and loperamide from its corporate office in Mississauga, Ontario, to participating Canadian institutions after Pharmacia Canada Inc. has received the following documentation from RTOG:
• Ethics committee approval letter clearly identified with protocol title and study-specific consent form, version dated; 
7.4.3
No dose modification will be made for Grade 1 or 2.
7.4.4
For Grade 3 or 4 neutropenia, the dose of CPT-11 should be held until toxicity resolves to Grade 1 and then should be reduced to 40 mg/m2.
7.4.5
For Grade 3 or 4 febrile neutropenia, the dose of CPT-11 should be held until toxicity resolves to Grade 1 and then should be reduced to 40 mg/m2.
7.4.6
For Grade 1 or 2 diarrhea, loperamide should be initiated (See Section 7.6.1).
7.4.7
For Grade 3 or 4 diarrhea while taking loperamide, see Section 7.2.5. Post-operative chemotherapy should be given to all patients with pathologic evidence of residual disease.
CPT-11 Dose Modification
Patients with a complete pathologic response may have their post-operative chemotherapy omitted at the discretion of the treating physicians. If significant treatment toxicity has occurred during the course of induction treatment, then the administration of the post-operative chemotherapy will be at the discretion of the treating physician.
7.5.2
Treatment can consist of 5-FU and leucovorin given for 4 cycles during five consecutive days on days 1-5, 29-33, 57-61, and 86-89 starting 4-6 weeks post-operatively. Leucovorin should be given as an i.v. bolus at a dose of 20 mg/m 2 /day for each of the 5 days in each cycle. This will be followed immediately on each day by 5-FU given as an i.v. bolus. 22 
7.5.3
For the first 2 courses of postoperative chemotherapy, the 5-FU dose will be 425 mg/m 2 /day. For the last 2 courses the 5-FU dose will be 350 mg/m 2 /day. In the event chemotherapy is scheduled to be delivered during five consecutive days in a given week and there are only four working days in that week (i.e. national holiday) then day 5 of chemotherapy should be given on the next available working day.
7.5.4
Alternatively, weekly bolus 5-FU 500 mg/m 2 given at the midpoint of a 2-hour infusion of leucovorin 500 mg/m 2 can be delivered weekly for 21 weeks. Dose modifications can be made at the discretion of the treating physician. 22 7.5. 5 If multiple toxicities are seen, the dose administered should be based on the most severe toxicity experienced. Dose reductions are based on the dose of chemotherapy given on the preceding treatment cycle, and should be based on toxicities observed since the previous dose of post-operative chemotherapy.
7.5.6
The dose of leucovorin will not be adjusted due to toxicity. It should remain at 20 mg/m 2 for all courses. Leucovorin will be given immediately prior to each 5-FU dose; thus, if 5-FU is delayed, leucovorin will be delayed. This applies only to the Mayo Schedule. If using the RPMI schedule per Section 7.4.3, this specific dosage does not apply. 
Supportive Therapy
All supportive therapy for optimal medical care will be given during the study period at the discretion of the attending physician(s) and documented on each institution's case report as source documentation.
7.6.1
Loperamide (Imodium) All patients should be instructed to begin taking loperamide at the earliest signs of diarrhea and/or abdominal cramping that occur more than eight hours after receiving CPT-11. Patients will be instructed to begin taking loperamide at the earliest signs of (1) a poorly formed or loose stool, (2) the occurrence of 1 to 2 more bowel movements than usual in one day, or (3) unusually high volume of stool. Loperamide should be taken in the following manner: 4 mg at the first onset of diarrhea, then 2 mg every two hours around the clock until diarrhea-free for at least 12 hours. Patients may take 4 mg of loperamide every four hours during the night. Additional antidiarrheal measures may be used at the discretion of the treating physician. Anticoagulants Patients who are taking Coumadin may participate in this study; however, it is recommended that prothrombin time be monitored carefully (at least weekly). Subcutaneous heparin or fractionated heparin products are also permitted.
7.6.6
Growth Factor Routine prophylactic use of G-CSF is not generally recommended; however, prophylactic administration of G-CSF in a patient who is experiencing recurrent difficulties with neutropenia or therapeutic use in patients with serious neutropenic complications such as tissue infection, sepsis syndrome, fungal infection, etc., may be considered at the investigator's discretion.
7.6.7
Other Concomitant Medication Other concomitant medications should be avoided except for analgesics, chronic treatments for concomitant medical conditions, or agents required for life-threatening medical problems. If possible, the use of drugs with laxative properties should generally be avoided because of the potential for exacerbation of diarrhea. Patients should be advised to contact the physician to discuss any laxative use.
7.6.8
Oral Hydration Oral fluids containing approximately 100 grams of sucrose and 2 grams of sodium chloride should be given on the day of CPT-11 administration and on day following CPT-11 administration.
7.7
Toxicity Reporting (6/20/01) 7.7. 1 The revised NCI Common Toxicity Criteria Version 2.0 (3/98) will be used to score chemotherapy and acute radiation (≤ 90 days) toxicities. The following guidelines for reporting adverse drug reactions (ADRs) apply to any research protocol, which uses commercial anticancer agents (also see Appendix V). The following ADRs experienced by patients accrued to these protocols and attributed to the commercial agent(s) should be reported to the Investigational Drug Branch, Cancer Therapy Evaluation Program, within 10 working days.
7.7.1.1
Any ADR which is both serious (life threatening, fatal) and unexpected. 7.7.1. 2 Any increased incidence of a known ADR which has been reported in the package insert or the literature.
7.7.1.3
Any death on study if clearly related to the commercial agent(s).
7.7.1.4
Acute myeloid leukemia (AML). The report must include the time from original diagnosis to development of AML, characterization such as FAB subtype, cytogenetics, etc. and protocol identification.
7.7.2
The ADR report should be documented on Form FDA 3500 and mailed to: 4 Results in persistent or significant disability or incapacity; 7.8.1. 5 Results in a congenital anomaly/birth defect in infants born to women treated on this protocol.
Medical and scientific judgment should be exercised in deciding whether expedited reporting is appropriate in those situations that may not be immediately life-threatening or result in death or hospitalization but that may jeopardize the patient or require intervention to prevent one of the events listed above.
If the investigator becomes aware of an SAE that occurs (regardless of relationship to study drug) within 30 days after stopping protocol therapy (i.e., after last dose); or more than 30 days after stopping protocol therapy, and is considered related to protocol therapy, the SAE must be reported in accordance with procedures specified in this protocol.
Serious Adverse Event Reporting Instructions
All serious adverse events must be reported as follows: Phone: 888-391-2222 The Therapeutic Products Directorate (TPD) of the Canadian Health Protection Branch will be notified by RTOG in an expedited manner of serious adverse events considered unexpected and related to protocol treatment. In addition, RTOG will inform all investigators of all serious adverse events reported to TPD and request that local ethics boards (REB/IRB/IEC) be notified of the same.
7.8.2.3
Reporting Serious Adverse Events to Local Ethics Boards Investigators must notify their Research Ethics Boards (REB/IRB/IEC) of any serious adverse events sent by RTOG for the purpose of reporting to REBs (as outlined in previous section). Documentation from the REB of receipt of these reportable serious adverse events must be kept on file in the centre.
SURGERY 8.1 Surgical Technique 8.1.1
Surgery will consist of a radical resection either by anterior resection or an abdominal perineal resection with preferably a total mesorectal resection four to ten weeks after completion of the chemoradiation therapy. Materials for patients entered on this study must be submitted to the RTOG Tissue Bank.
OTHER THERAPY
10.1.2
The following must be provided:
10.1.2.1
One H&E stained slide.
10.1.2.2
A paraffin-embedded tissue block of the tumor or 15 unstained slides. Block/slides must be clearly labeled with the pathology identification number that agrees with the pathology report.
10.1.2.3
Pathology report documenting that submitted block or slides contain tumor.
10.1.2.4
A Pathology Submission Form must be included and must clearly state that it is being submitted for the RTOG Tissue Bank.
10.1.3
RTOG will reimburse pathologists from submitting institutions $100. per case if proper materials are submitted (reimbursement is handled through an invoice submitted to RTOG Administration, ATT: Path Reimbursement).
10.1.4
Patient consent form should give the Pathology Department authority and responsibility to comply with this request (pathology blocks belong to the patient from whom tissue has been removed).
10.1.5
Materials will be sent to: A complete pathologic assessment of the primary cancer will be made to assess depth of invasion, grade, mucin production, and blood vessel (with special stains wherever possible), lymphatic or perineural invasion. The deep and lateral margins will be assessed in millimeters and specifically defined as deep, lateral, superior, or inferior margins. Intra-operative frozen section will be used to assess the adequacy of the margin of resection.
LDS Hospital
10.2.2
The circumferential margins will be inked prior to fixation. The size of the specimen will be measured in length, width and thickness following fixation. The size of the tumor will be measured in length, width and thickness in fixed condition. The pathology report will indicate the absence of microscopic tumor at the proximal, distal, lateral, and deep margins of resection. The central portion of the tumor will be serially sectioned to determine the maximum depth of cancer penetration.
10.2.3
The pathology report will specify the presence or absence of mucin production. A cancer will be scored as mucin positive if 30% or more of cells are producing mucin. The pathology report will specify the presence or absence of signet ring cell morphology and a cancer will be considered a signet ring cell cancer if 90% or more of cells exhibit this morphology. The pathology report will report the presence or absence of colloid cancer morphology.
The pathology report will specify depth of invasion of tumor in a fashion such that it is clear whether the tumor is: 1) Confined to the mucosa 2) Confined to submucosa 3) Confined to muscularis propria 4) Transmural into perirectal fat grossly or microscopically 10.2. 4 The pathology report will specify histologic grade as follows: 
As indicated a. CBC and platelets will be done weekly during RT. b. For corroboration of TNM staging (optional) c. Labs within four weeks prior to study entry; scans within eight weeks prior to study entry. d. Recommended for follow-ups, not required.
Documentation of Tumor Response
Tumor response to high-dose preoperative radiation will be evaluated following surgical resection and pathological assessment of the specimen and categorized according to the following criteria:
11.2.1
Complete response: No evidence of residual cancer.
11.2.2
Partial response: > 50% regression of tumor.
11.2.3
No response: No change in size.
11.2.4
Progression: Increase in size.
Documentation and Diagnosis of Tumor Relapse 11.3.1
The following terminology will be used to document evidence of locally recurrent or metastatic disease: 11.3.1.1
Local Failure: recurrence or persistence of disease within radiation portals.
11.3.1.2
Regional Failure: failure outside of treatment field on basis of direct and/or lymphatic spread to include aortic nodes.
11.3.1.3
Distant Failure: includes both peritoneal seeding (PS) and distant metastasis (DM) on hematologic basis.
11.3.1.4
Disease Relapse: will be documented by biopsy whenever possible, together with clinical or radiographic evidence.
11.3.1.5
Progression: defined as one of the following: a. Evidence of new areas of malignant disease (palpable or measurable). b. Liver metastasis diagnosed by clinically significant hepatomegaly and/or positive liver scan. c. Other evidence of progression, e.g., jaundice, ascites, pleural effusion-Class V, persistent sacral pain with or without x-ray verification of bone destruction, neurologic changes consistent with metastatic disease with positive brain or CT scan.
11.3.2
At the time of disease progression while undergoing treatment, the patient will be taken off protocol treatment; however, follow-up for evaluation will continue until death. The patient can be treated at the discretion of their physician. (2/25/03) 11.4 Assessments 11.4.1
Complications of treatment will be recorded as to site and severity.
11.4.2
The major complaint is most likely to be GI related, and documentation of this will be extremely important to help evaluate treatment complications. Treatment will be conservative whenever possible, with surgical intervention called upon only when conservative methods fail.
11.4.3
Patients who have evidence of locoregional failure either by scans or clinical examination will undergo exploratory laparotomy and radical resection if possible. The radical resection will be appropriate for the site of recurrence.
Patients will receive full supportive care, including transfusions of blood and blood products, antibiotics, antiemetics, etc., when appropriate. Treatment with chemotherapeutic agents or radiation can be administered as necessary for recurrent or metastatic disease.
11.4.4
Associated medical disease will be evaluated and treated as per accepted practice. Complete Resection Rate
13.1.4
Patterns of Failure 13.1.5 Survival
Sample Size
The sample size consideration is based on the pathological complete response (pCR). A disease progression or death before surgery will be considered as a less than pCR (even without surgical specimen), and will be included in the denominator where the path CR rate is calculated. A search of available literature shows that the pCR rate in this disease has been reported in the 10-20% range overall. An experimental arm that results in a pCR rate of less than 20% would not merit further study. Patients will be randomized to one of two experimental arms. We are targeting 45 patients for each of the two arms. Confidence intervals corresponding to various potential pCR rates are listed in Table 1 . With type I error of 0.05 (one sided) and statistical power of more than 90%, this sample size is will be able to detect a minimum of 20% increase in pCR compared with historical pCR (which can be as high as 20%). Adjusting the sample size by 10% guarding against ineligible cases, we will need to randomize 50 patients per each arm. Thus the targeted study size will be 100. The Fleming design will be used to identify early if either or both arms have unacceptably lower response rate. 23 If both arms yield an estimated pCR > 20%, we will use statistical selection theory to choose the arm for further testing in the follow-up phase III trial. 24 Briefly, its criterion is to select the treatment arm with highest response regardless how small or "nonsignificant" its advantage over the other treatment is. With 45 patients in each arm, we have greater than a 90% probability of correctly selecting the better treatment when there is an absolute difference of 15% in response rates between the two experimental arms. 25 
Drug Modifications for Unacceptable Toxicity
Because of limited phase I testing with both treatment plans, they will separately be monitored for excessive toxicity using the method of Fleming. 23 The toxicities, that will be monitored, are grade 3 and 4 and are anticipated to occur during treatment.
The frequency of grade 3 or 4 toxicities would be acceptable if it is no more than 10%. Modifications to either treatment plan will be considered if its frequency is more than 30%. If there five or more patients with grade 3 or 4 toxicities among the first 15 patients in a treatment arm, or if there are seven or more such cases among the first 30 patients entered, the treatment plan may be modified for the remaining patients to be entered. The modification will be only made after a conference call or meeting of the GI Steering Committee and the study chairs.
If there is any fatal treatment related toxicity on a treatment arm, it will be immediately reviewed by the study chairs and followed by a conference call with the GI Steering Committee to determine if a dose modification is warranted. If there are two such fatal treatment toxicities on a treatment arm, accrual will be immediately suspended pending such review.
13.4
Accrual for the Study Based upon wider use of pre-operative radiation therapy for rectal cancer and the results of the RTOG institutional survey, we estimate a monthly accrual for this study of five patients and anticipate that the accrual can be achieved in 18 months allowing two months for institutional IRB approvals. If the monthly accrual rate is less than 2.5 cases a month after the first year, the study will be re-evaluated.
Randomization Plan
Patients will be stratified before randomization with respect to tumor clinical stage (T3 vs. T4). The treatment allocation scheme described by Zelen will be used because it balances patient factors other than institution. 27 
13.6
Analyses Plan 13.6.1
Early Termination of Treatment Arms
There will be two interim looks at the data. The first will come after the first 15 patients have been entered onto an arm. If at that time only 1 patient has experienced a path CR, we will accept the null hypothesis and the arm will be dropped from further randomization. The second look will come after a total of 30 patients have been entered onto a treatment arm. We will accept the null hypothesis if there are 7 or fewer pCRs at that time. 23 Alternately, the boundary for stopping an arm and rejecting the null hypothesis will be reached if there are 8 pCRs among the first 15 patients or 11 among the first 30 patients. If this boundary is crossed, the results will be forwarded to the GI Committee, which will determine whether the arm should be closed and considered in a future phase III study.
13.6.2
Interim Analysis Interim reports with statistical analyses are prepared every six months until the initial manuscript reporting the treatment results has been submitted. In general, the interim reports will contain information about: a. The patient accrual rate with a projected completion date for the accrual phase; b. The compliance rate of treatment delivery with respect to protocol prescription; c. The quality of submitted data with respect to timeliness and completeness, and accuracy; d. The frequency and severity of toxicities; Through examining the above items, the study chairs and the statistician can identify problems with the execution of the study. These problems will be reported to the RTOG GI committee responsible for the study and, if necessary, to the RTOG Research Strategy Committee, so that corrective action can be taken.
Analysis for Reporting the Initial Treatment Results (2/25/03)
To preserve the overall 0.05 type I error adjusting for the two early looks, we will reject the null hypothesis of 20% path CR rate for any given treatment arm if there are at least 14 pCRs achieved. The initial analysis of treatment results will be performed after all patients have been followed at least 3 months post surgery. All eligible patients (as per Section 3.0) that begin protocol treatment will be included in the analysis. It should be noted that patients who had disease progression or died before surgery will be considered as a less than pCR (even without surgical specimen) and will be included in the denominator when the pCR rate is calculated. The usual components of this analysis are: a. Tabulation of all cases entered, and any excluded from the analysis along with reasons for the exclusion; b. Institutional accrual; c. Distribution of important prognostic baseline variables; d. Distribution of treatment related toxicities; e. Observed results with respect to the endpoints described above. The 95% confidence interval for the treatment's pCR rate will be estimated. f. Selection of the treatment arm with higher pCR rate if both are greater than 20%. If the difference between the two arms is less than 10%, toxicity differences will be considered in finalizing the treatment selection.
Analysis for Reporting the Long Term Treatment Results (2/25/03)
The second analysis of treatment results will be performed after all patients have been followed at least 3 years. All eligible patients (as per Section 3.0) that begin protocol treatment will be included in the analysis. It should be noted that patients who had disease progression or died before surgery will be included in the analysis. The focus of this analysis will be on disease recurrence patterns. It will include items a-d from Section 13.6.3.
Inclusion of Women and Minorities
We would anticipate a similar distribution of race and gender in this study as was seen in INT 0144/RTOG 94-03. In that study, 36% of the patients were women and 15% were non-white. The projected race/gender distribution for this study is shown in Table 2 . 
WHY IS THIS STUDY BEING DONE?
The purpose of this study is to examine two different ways to give chemotherapy and radiation therapy to patients before they undergo surgery. We want to find out what effects (good and bad) each of these treatment schedules has on rectal cancer. This research is being done because although surgery is the standard treatment for advanced rectal cancer, there is a high rate of recurrence. We want to find out if radiation and chemotherapy given prior to surgery will help control this disease. Having chemotherapy and radiotherapy before surgery may also reduce the tumor size so that less extensive surgery may be necessary.
HOW MANY PEOPLE WILL TAKE PART IN THE STUDY
Nationally, about 100 people will take part in this study.
WHAT IS INVOLVED IN THE STUDY?
You will be "randomized" into one of the study groups described below. Randomization means that you are put into a group by chance. It is like flipping a coin. Which group you are put in is done by a computer. Neither you nor the researcher will choose what group you will be in. You will have an equal chance of being placed in one of the following two groups.
Arm 1:
Radiation Therapy: Twice a day (6 hours apart), five days per week for five weeks.
Chemotherapy: Beginning on the first day of radiation therapy, 5-FU delivered continuously by an intravenous pump until the end of radiation therapy. The pump will be portable allowing you to get around. Surgery:
Removal of tumor four to ten weeks after radiation ends.
Arm 2:
Radiation Therapy: Once a day, five days per week for six weeks. Chemotherapy:
Beginning on the first day of radiation therapy, 5-FU delivered continuously (5 days a week) by an intravenous pump until the end of radiation therapy. The pump will be portable allowing you to get around. Irinotecan (CPT-11) will be given intravenously over 60 minutes once a week for 4 weeks just prior to your radiation therapy treatment. Surgery:
If you take part in this study, you will have the following tests and procedures:
• 
HOW LONG WILL I BE IN THE STUDY?
You will receive radiation therapy and chemotherapy for five to six weeks and six to eight weeks later you will undergo surgery. After your surgery you will be seen by your doctor once every three months for two years, then every six months for three years and after that once a year for the rest of your life.
You can stop participating at any time. However, if you decide to stop participating in the study, we encourage you to talk to the researcher and your regular doctor first.
If you do not complete the prescribed treatment you will still have regular checkups with your doctor for the rest of your life unless you choose to remove yourself from the study. You will have these checkups once every three months for two years, then once every six months for three years and then once a year after that.
The researcher may decide to take you off this study if your disease gets worse despite the treatment, the side effects of the treatment are too dangerous for you, or new information about the treatment becomes available and this information suggests the treatment will be ineffective or unsafe for you. It is unlikely, but the study may be stopped early due to lack of funding or participation.
WHAT ARE THE RISKS OF THE STUDY?
While on the study, you are at risk for these side effects. You should discuss these with the researcher and/or your regular doctor. There also may be other side effects that we cannot predict. Other drugs will be given to make side effects less serious and uncomfortable. Many side effects go away shortly after the radiation therapy and chemotherapy are stopped, but in some cases side effects can be serious or long-lasting or permanent. Other risks: In studies where radiotherapy was given before surgery, there was evidence of a somewhat higher risk of developing skin infections in the area of radiation. This risk was low overall and, generally, these infections resolved with local care and antibiotics. However, should you develop this type of infection, it may prolong your hospital stay for a few days. . Allergic reactions have been reported in less than one percent of patients.
Risks Associated with Radiation Therapy
Reproductive risks: Because the radiation and drugs in this study will affect an unborn baby, you should not become pregnant or father a baby while on this study. You should not nurse your baby while on this study. Ask about counseling and more information about preventing pregnancy
ARE THERE BENEFITS TO TAKING PART IN THE STUDY?
If you agree to take part in this study, there may or may not be direct medical benefit to you. We hope the information learned from this study will benefit other patients with rectal cancer in the future.
WHAT OTHER OPTIONS ARE THERE?
You may choose to not participate in this study. Other treatments that could be considered for your condition may include the following: (1) radiation therapy; (2) chemotherapy; (3) surgery; or (4) no treatment except medications to make you feel better. With the latter choice, your tumor would continue to grow and your disease would spread. These treatments could be given either alone or in combination with each other.
Another option may be to get the treatment plan described in this study at this center or another center even if you do not take part in the study.
Your doctor can tell you more about your condition and the possible benefits of the different available treatments. Please talk to your regular doctor about these and other options.
WHAT ABOUT CONFIDENTIALITY?
Efforts will be made to keep your personal information confidential. We cannot guarantee absolute confidentiality. Records of your progress while on the study will be kept in a confidential form at this institution and in a computer file at the headquarters of the Radiation Therapy Oncology Group (RTOG). Your personal information may be disclosed if required by law.
Organizations that may inspect and/or copy your research records for quality assurance and data analysis include groups such as the Food and Drug Administration (FDA), the National Cancer Institute (NCI), qualified representatives of applicable drug manufacturers, and other groups or organizations that have a role in this study.
WHAT ARE THE COSTS?
Taking part in this study may lead to added costs to you or your insurance company. Please ask about any expected added costs or insurance problems.
In the case of injury or illness resulting from this study, emergency medical treatment is available but will be provided at the usual charge. No funds have been set aside to compensate you in the event of injury.
You or your insurance company will be charged for continuing medical care and/or hospitalization.
You will receive no payment for taking part in this study.
WHAT ARE MY RIGHTS AS A PARTICIPANT?
Taking part in this study is voluntary. You may choose not to take part or may leave the study at any time. Leaving the study will not result in any penalty or loss of benefits to which you are entitled.
We will tell you about new information that may affect your health, welfare, or willingness to stay in this study.
A Data Safety and Monitoring Board, an independent group of experts, may be reviewing the data from this research throughout the study. We will tell you about the new information from this or other studies that may affect your health, welfare, or willingness to stay in this study.
WHOM DO I CALL IF I HAVE QUESTIONS OR PROBLEMS?
(This section must be completed) 
2
Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours (Karnofsky 50-60).
3
Capable of only limited self-care, confined to bed or chair 50% or more of waking hours (Karnofsky 30-40).
4
Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair (Karnofsky [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Colon and Rectum, 5 th Edition
APPENDIX III
AJCC Staging
DEFINITION OF TNM
The same classification is used for both clinical and pathologic staging.
Primary Tumor (T)
TX Primary tumor cannot be assessed T0
No evidence of primary tumor Tis Carcinoma in situ: intraepithelial or invasion of lamina propria* T1
Tumor invades submucosa T2
Tumor invades muscularis propria T3
Tumor invades through the muscularis propria into the subserosa, or into nonperitonealized pericolic or perirectal tissues T4
Tumor directly invades other organs or structures, and/or perforates visceral peritoneum** * Note: Tis includes cancer cells confined within the gladular basement membrane (intraepithelial) or lamina propria (intramucosal) with no extension through the muscularis mucosae into the submucosa. ** Note: Direct invasion in T4 includes invasion of other segments of the colorectum by way of the serosa; for example, invasion of the sigmoid colon by a carcinoma of the cecum. T1  N0  M0  A  T2  N0  M0  -Stage II  T3  N0  M0  B  T4  N0  M0  -Stage III  Any T N1  M0  C  Any T N2 M0 -Stage IV Any T Any N M1 -
Regional Lymph Nodes (N)
NX
C. ADVERSE DRUG REACTIONS DRUG AND BIOLOGICS
An adverse reaction is a toxicity or an undesirable effect usually of severe nature. Specifically, this may include major organ toxicities of the liver, kidneys, cardiovascular system, central nervous system, skin, bone marrow, or anaphylaxis. These undesirable effects may be further classified as "known" or "unknown" toxicities.
Known toxicities are those which have been previously identified as having resulted from administration of the agent. They may be identified in the literature, the protocol, the consent form or noted in the drug insert.
Unknown toxicities are those thought to have resulted from the agent but have not previously been identified as a known side effect.
Commercial and Non-Investigational Agents
i. Any fatal (grade 5) or life threatening (grade 4) adverse reaction which is due to or suspected to be the result of a protocol drug must be reported to the Group Chairman or to RTOG Headquarters' Data Management Staff and to the Study Chairman by telephone within 24 hours of discovery. Known grade 4 hematologic toxicities need not be reported by telephone.
ii. Unknown adverse reactions (> grade 2) resulting from commercial drugs prescribed in an RTOG protocol are to be reported to the Group Chairman or RTOG Headquarters' Data Management, to the Study Chairman and to the IDB within 10 working days of discovery. FDA Form 3500 is to be used in reporting details. All relevant data forms must accompany the RTOG copy of Form 3500.
iii. All neurotoxicities (> grade 3) from radiosensitizer or protector drugs are to be reported within 24 hours by phone to RTOG Headquarters and to the Study Chairman.
iv. All relevant data forms must be submitted to RTOG Headquarters within 10 working days on all reactions requiring telephone reporting. A special written report may be required.
Reactions definitely thought not to be treatment related should not be reported, however, a report should be made of applicable effects if there is a reasonable suspicion that the effect is due to protocol treatment.
Investigational Agents
Prompt reporting of adverse reactions in patients treated with investigational agents is mandatory. RTOG Headquarters. **A written report to follow within 10 working days.
-All deaths within 30 days As above of termination of the agent.
-All life threatening (grade 4)
As above events which may be due to agent. Study Chairman and IDB within 24 hours. resulting from or suspected to be related **A written report to follow within 10 to investigational agent.
working days.
-All grade 2, 3 unknown adverse reactions **Report in writing to RTOG Headquarters and resulting from or suspected to be related IDB within 10 working days. to investigational agent.
** See attached (if applicable to this study) NCI Adverse Drug Reaction Reporting Form
Requests for trial drug resupply:
Trial site pharmacist
• Manages trial drug inventory ensuring sufficient supplies are maintained for 4 weeks of treatment for 3 patients
• Completes the request for trial drug shipment on an "as needed" basis, depending upon patient accrual.
• Sends the request for trial drug shipment to the Pharmacia Canada Inc. Clinical
Trial Supplies Manager @ FAX number (905) 755-3151 .
Pharmacia Canada Inc. Clinical Trial Supplies Manager
• Forwards the request to the Therapeutic Area Manager, MMCR.
Pharmacia Canada Inc. TherapeuticArea Manager, MMCR
• Approves and signs the request for trial drug shipment.
• Forwards the request for trial drug shipment to the Clinical Trial Supplies Manager.
Pharmacia Canada Inc. Clinical Trial Supplies Manager
• Ships drug supplies to the trial site.
• Requests the Clinical Research Coordinator, MMCR to notify the trial site of the shipment.
Pharmacia Canada, Clinical Research Co-ordinator, MMCR
• Notifies the trial pharmacist and site study coordinator of the shipment by fax.
Trial site pharmacist
• Confirms receipt of the trial drugs by signing and dating the Drug Shipment
Invoice that accompanies the trial drug supplies.
• Sends a signed/dated copy of the Drug Shipment Invoice to the Clinical Trial Supplies Manager, Pharmacia Canada @ FAX number (905) 755-3151.
Return of trial drug supplies:
Pharmacia Canada Inc. Clinical Research Coordinator, MMCR
• Forwards the "Return of Clinical Supplies" form to the trial site.
• Sends written instruction to the trial site regarding shipment of returned goods to Pharmacia Canada offices for destruction. (3-13-02) 
APPENDIX VII
RTOG R-0012/ CPTAIV-0020-359 SITE INFORMATION SHEET
To facilitate the timely receipt of drug shipments, supplies and correspondence, we ask that you complete and promptly return this form to RTOG by faxing 215-574-0300. Your careful attention to the accuracy of this form will ensure the correct delivery of all items associated with this clinical trial. 
INVESTIGATOR
